Navigation Links
AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors,and In Vivo Results for a GHRH Antagonist at the AACR Annual,Meeting in Los Angeles

he treatment of early and metastatic breast cancer.

Copies of these abstracts are currently available and can be viewed on-line through the AACR 2007 Meeting website at: http://www.abstractsonline.com/viewer/?mkey=%7BE3F4019C%2D0A43%2D4514%2D8F66%2DB86DC90CD935%7D

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global, pure play biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.

    News releases and additional information are available at

    www.aeternazentaris.com


    Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes", "anticipates", "intends", "plans", "expects", "estimates", "will," "may", "should", "approximately", and the negative or other variations of those terms or comparable terminology, are forward-looking statements. Such statements reflect management's current views, intentions, strategies and plans and are based on certain assumptions.

Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the ability of AEterna Zentaris to implement its business strategies, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of AEterna Zentaris
'"/>




Page: 1 2 3

Related medicine technology :

1. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
2. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
3. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. The Past, Present and Future of HLA Typing
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
Post Your Comments:
(Date:12/19/2014)... Dec. 18, 2014  Decision Resources Group finds that ... States will increase to a value of ... driven by expansion in the large direct energy device ... be increasingly adopted due to the advantages they offer ... key findings from Decision Resources Group,s coverage of the ...
(Date:12/19/2014)... Ky. , Dec. 18, 2014 Baptist Health ... States to receive full Atrial Fibrillation with Electrophysiology ... Care (SCPC). Atrial fibrillation is the most common ... that in some cases can lead to stroke and possible ... United States have atrial fibrillation and the numbers ...
(Date:12/19/2014)... and LYON, France , Dec. 19, ... LLY ) and Adocia (Euronext Paris: FR0011184241 – ADOC) ... an ultra-rapid insulin, known as BioChaperone Lispro, for treatment ... BioChaperone Lispro relies on Adocia,s proprietary BioChaperone® technology and ... and Adocia will develop BioChaperone Lispro with the goal ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
(Date:12/19/2014)... 19, 2014 Energy Textiles is ... now available. Celliant, the world’s leading responsive textile, ... pillowcases. , There are a number of benefits ... increased oxygenation and balanced body temperature; which can ... pain relief; enhanced athletic performance; and overall wellness. ...
(Date:12/19/2014)... Santa Rosa, CA (PRWEB) December 19, 2014 ... 2x4 and 5x5 SuperClone Rooms. SuperCloset continues to offer ... grow solutions. Pair one of the new SuperClone Rooms ... truly professional, perpetual, and turnkey indoor hydroponic grow room ... cloner in the world, SuperCloset’s SuperPonic SuperCloner 50 ...
(Date:12/19/2014)... 2014 An evening dress is perfect for ... closet. Discount-Dress.com, a distinguished dresses retailer, has unveiled its new ... in this great shopping platform. Customers can view ... hard work, Discount-Dress.com has been accepted and praised by customers ... easier shopping stage for clients. In order to expand its ...
(Date:12/19/2014)... (HealthDay News) -- New research warns parents that buying an older ... Nearly half of teen drivers killed in the United States ... 11 years old and often lacked important safety features that are ... teen drivers killed in crashes were in cars at least six ... old, 31 percent were in cars 11 to 15 years old, ...
(Date:12/19/2014)... -- Potentially illness-causing E. coli bacteria were found on ... to a new study. Researchers checked cilantro, basil ... markets in Los Angeles and Orange counties in California, ... samples tested, 24 percent were positive for E. coli. ... researchers. Both types of bacteria can cause sometimes ...
Breaking Medicine News(10 mins):Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2Health News:Older Cars a Bad Choice for Younger Drivers 2Health News:E. Coli Germs Found on Farmers Market Herbs 2
... pass,companion bill and send measure to President, ALBANY, ... of the Protecting the Medicaid Safety Net Act of,2008, ... The bill,prevents massive increases in costs for people in ... "Today,s vote is a victory for all New York ...
... antibiotics sufficient to treat eye disease, study finds ... communities with moderate levels of the eye disease trachoma, ... with the antibiotic azithromycin may be sufficient to eliminate ... at the London School of Hygiene & Tropical Medicine,s ...
... needed to prove that oversulfated chondroitin sulphate caused deaths, ... researchers say they,ve confirmed that lots of the blood ... a man-made chemical called oversulfated chondroitin sulfate. , ... Biotechnology . , And, according to a paper published ...
... at the Congressional Gold Medal ceremony in the Capitol ... Below are the,Speaker,s remarks:, "Good morning. It is ... the House and Senate to honor Dr. Michael DeBakey. ... Representative Al,Green, and others who worked with them for ...
... 75-cent Per Pack Increase Would Help Raise $390 ... Ohio leaders should,fund a proposed economic stimulus plan ... prevention funds, recommends a report released,today by the ... this tobacco tax alternative would reduce smoking, save ...
... Corporation,(NYSE: STE ) today announced that its Board ... amount of $0.06 per common share. The,dividend is payable ... close of,business on May 14, 2008., About STERIS, ... a healthier today and,safer tomorrow through knowledgeable people and ...
Cached Medicine News:Health News:AARP Thanks New York's Representatives for Supporting Bill to Protect People in Medicaid 2Health News:Annual Trachoma Treatments May Be Unnecessary 2Health News:Researchers Identify Contaminant in Tainted Heparin 2Health News:Researchers Identify Contaminant in Tainted Heparin 3Health News:Pelosi: 'By Literally Fixing Broken Hearts, Dr. DeBakey Has Given Hope and Health to Millions' 2Health News:New Report: Increasing Ohio's Tobacco Tax Would Fund Economic Stimulus Plan and Preserve Highly-Successful Tobacco Prevention Program 2Health News:New Report: Increasing Ohio's Tobacco Tax Would Fund Economic Stimulus Plan and Preserve Highly-Successful Tobacco Prevention Program 3Health News:New Report: Increasing Ohio's Tobacco Tax Would Fund Economic Stimulus Plan and Preserve Highly-Successful Tobacco Prevention Program 4Health News:STERIS Corporation Declares Regular Quarterly Dividend 2Health News:STERIS Corporation Declares Regular Quarterly Dividend 3
... Triad Plus PVP-I Prep Gel ... PVP-I Prep Gel is film forming, ... action that has been known to ... gram-positive bacteria (including antibiotic resistant), fungi, ...
... HIBICLENS bonds with ... a protective, germ-killing field. ... fast acting antimicrobial effect, ... irritation potential promotes compliance ...
Aplicare's disposable 1-ounce pouches are designed for individual application and are ideal for reducing waste. They are used in nursing homes, home healthcare settings, blood banks, laboratories, em...
Aplicare's disposable 1-ounce pouches are designed for individual application and are ideal for reducing waste. They are used in nursing homes, home healthcare settings, blood banks, laboratories, em...
Medicine Products: